Chemotherapy News and Research

Latest Chemotherapy News and Research

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

The European Commission has licensed Avastin in combination with standard chemotherapy for the treatment of women with advanced cervical cancer. Until now, the treatment has been available ahead of licence to eligible patients in England via individual requests to the Cancer Drugs Fund (CDF).

28 Apr 2015

Research findings could offer new way to test for chemo brain in patients

UBC research shows that chemotherapy can lead to excessive mind wandering and an inability to concentrate. Dubbed 'chemo-brain,' the negative cognitive effects of the cancer treatment have long been suspected, but the UBC study is the first to explain why patients have difficulty paying attention.

28 Apr 2015

Molecular Health granted European patent for novel Erythropoietin receptor

Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.

27 Apr 2015

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.

From Baxter International Inc. 27 Apr 2015

OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers.

27 Apr 2015

Increasing radiotherapy can significantly improve survival for children with intracranial ependymoma

Two studies to be presented today (Sunday) at the 3rd ESTRO Forum in Barcelona, Spain, show that increasing the dose of radiotherapy given to children with an intracranial ependymoma, a form of cancer of the central nervous system, can significantly improve their survival.

27 Apr 2015

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Ahmad M. Khalil, PhD, knew the odds were against him -- as in thousands upon thousands to one. Yet he and his team never wavered from their quest to identify the parts of the body responsible for revving up one of the most aggressive forms of breast cancer, HER2+. This month in Breast Cancer Research and Treatment, Khalil and his colleagues at Case Western Reserve University proved the power of persistence; from a pool of more than 30,000 possibilities, they found 38 genes and molecules that most likely trigger HER2+ cancer cells to spread.

25 Apr 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

Oncologists publish review of advanced clinical treatments for pancreatic cancer

The oncologists Manuel Hidalgo, Director of the Clinical Research Programme of the Spanish National Cancer Research Centre, and Ignacio Garrido-Laguna, member of the Experimental Therapeutics Program at Huntsman Cancer Institute of the University of Utah (USA), have recently published a review of state-of-the-art clinical treatments for pancreatic cancer -- including the most current therapies and innovative research -- in the prestigious scientific journal Nature Reviews Clinical Oncology.

24 Apr 2015

Penn researchers find molecular bond between DNA damage, cellular senescence and premature aging

Like a beloved pair of jeans, human DNA accumulates damage over time, and older people's bodies can't repair it as well. Many scientists believe a build up of damage can cause cells to enter an irreversible dormant state known as senescence. Cellular senescence is believed to be responsible for some of the telltale signs of aging, such as weakened bones, less resilient skin and slow-downs in organ function.

24 Apr 2015

Study shows that Hodgkin lymphoma patients can remain disease-free with just chemotherapy alone

In a paper published in the New England Journal of Medicine, the scientists show that a positron-emission tomography (PET) scan immediately after treatment with chemotherapy can identify patients who have a very good outcome without additional radiotherapy.

23 Apr 2015

Purdue University study sheds light on how decitabine drug reverses cell damage

A Purdue University study sheds light on how cell damage is reversed by the cancer drug decitabine and identifies a potential biomarker that could indicate a patient's stage of cancer and response to treatment.

23 Apr 2015

IMIM researchers identify new way of treating colorectal cancer

Researchers at the Institut Hospital del Mar d'Investigacions Mèdiques (IMIM) have identified a new way of treating colorectal cancer. In the study published in the journal Science Signaling, the team led by LLuís Espinosa, investigator of IMIM's research group into stem cells and cancer, have shown that inhibition of endosomal activity is a potential therapeutic strategy for the treatment of cancers with the BRAF mutated gene.

23 Apr 2015

Discovery unveils novel drug targets to halt peripheral neuropathies, neurodegenerative disorders

New research highlights how nerves - whether harmed by disease or traumatic injury - start to die, a discovery that unveils novel targets for developing drugs to slow or halt peripheral neuropathies and devastating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS).

22 Apr 2015

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

The botanical extract honokiol, a biologically active molecule isolated from the bark of Magnolia spp., holds promise as an adjunct treatment for aggressive bladder and kidney cancers, as reported in two new studies. New research on honokiol in bladder cancer was presented at the American Association for Cancer Research Annual Meeting 2015.

22 Apr 2015

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer.

22 Apr 2015

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Acacia Pharma Ltd, the supportive care company developing products for US and international markets, announces the initiation of a Phase 3 study investigating APD421 in combination with standard anti-emetics, in the prevention of post-operative nausea & vomiting (PONV) in high-risk patients. PONV remains a clinically significant problem in patients undergoing surgery, despite the availability of a range of anti-emetic medications.

21 Apr 2015

Study attributes mild cognitive defects in women to post-traumatic stress induced by cancer diagnosis

Breast cancer patients often display mild cognitive defects even before the initiation of chemotherapy. A new study by Ludwig-Maximilians-Universitaet in Munich researchers now attributes the syndrome to post-traumatic stress induced by diagnosis of the disease.

21 Apr 2015

Global changes in cancer cells' epigenome may determine disease progression

Genomic studies have illuminated the ways in which malfunctioning genes can drive cancer growth while stunting the therapeutic effects of chemotherapy and other treatments. But new findings from Weill Cornell Medical College investigators indicate that these genes are only partly to blame for why treatment that was at one point effective ultimately fails for about 40 percent of patients diagnosed with the most common form of non-Hodgkin Lymphoma.

21 Apr 2015

Designing AR Inhibitors Team wins AACR Team Science Award for developing prostate cancer treatment

The American Association for Cancer Research will award the ninth annual AACR Team Science Award to the Designing Androgen Receptor (AR) Inhibitors Team from Memorial Sloan Kettering Cancer Center and the University of California, Los Angeles at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

21 Apr 2015

Chemotherapy News and Research

Latest Chemotherapy News and Research

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

Research findings could offer new way to test for chemo brain in patients

Molecular Health granted European patent for novel Erythropoietin receptor

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

OncoGenex terminates agreement with Teva, regains rights to custirsen

Increasing radiotherapy can significantly improve survival for children with intracranial ependymoma

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Oncologists publish review of advanced clinical treatments for pancreatic cancer

Penn researchers find molecular bond between DNA damage, cellular senescence and premature aging

Study shows that Hodgkin lymphoma patients can remain disease-free with just chemotherapy alone

Purdue University study sheds light on how decitabine drug reverses cell damage

IMIM researchers identify new way of treating colorectal cancer

Discovery unveils novel drug targets to halt peripheral neuropathies, neurodegenerative disorders

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Study attributes mild cognitive defects in women to post-traumatic stress induced by cancer diagnosis

Global changes in cancer cells' epigenome may determine disease progression

Designing AR Inhibitors Team wins AACR Team Science Award for developing prostate cancer treatment

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in